Xeris Biopharma Holdings, Inc.
XERS
$5.70
-$0.015-0.26%
Weiss Ratings | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | E | |||
Rating Factors | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Good | |||
Efficiency Index | Very Weak | |||
Solvency Index | Fair | |||
Total Return Index | Fair | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 1.70 | |||
Price History | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | 9.10% | |||
30-Day Total Return | 59.08% | |||
60-Day Total Return | 66.03% | |||
90-Day Total Return | 80.79% | |||
Year to Date Total Return | 64.60% | |||
1-Year Total Return | 179.17% | |||
2-Year Total Return | 348.43% | |||
3-Year Total Return | 111.71% | |||
5-Year Total Return | -- | |||
52-Week High % Change | -5.93% | |||
52-Week Low % Change | 237.87% | |||
Price | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $6.07 | |||
52-Week Low Price | $1.69 | |||
52-Week Low Price (Date) | Apr 19, 2024 | |||
52-Week High Price (Date) | Mar 26, 2025 | |||
Valuation | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 879.00M | |||
Enterprise Value | 1.08B | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -0.38 | |||
Earnings Per Share Growth | -16.87% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 4.19 | |||
Price/Book (Q) | -28.81 | |||
Enterprise Value/Revenue (TTM) | 5.31 | |||
Price | $5.70 | |||
Enterprise Value/EBITDA (TTM) | -69.71 | |||
Enterprise Value/EBIT | -39.16 | |||
Market Cap Category | Small Cap | |||
Dividends and Shares | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 149.09M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 844 445 5704 | |||
Address | 1375 West Fulton Street Chicago, IL 60607 | |||
Website | www.xerispharma.com | |||
Country | United States | |||
Year Founded | 2005 | |||
Profitability | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -13.56% | |||
Profit Margin | -27.00% | |||
Management Effectiveness | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -5.33% | |||
Return on Equity | -- | |||
Income Statement | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 203.07M | |||
Total Revenue (TTM) | 203.07M | |||
Revenue Per Share | $1.36 | |||
Gross Profit (TTM) | 166.24M | |||
EBITDA (TTM) | -15.48M | |||
EBIT (TTM) | -27.55M | |||
Net Income (TTM) | -54.84M | |||
Net Income Avl. to Common (TTM) | -54.84M | |||
Total Revenue Growth (Q YOY) | 35.39% | |||
Earnings Growth (Q YOY) | 61.81% | |||
EPS Diluted (TTM) | -0.38 | |||
EPS Diluted Growth (Q YOY) | 64.60% | |||
Balance Sheet | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 71.62M | |||
Cash Per Share (Q) | $0.48 | |||
Total Current Assets (Q) | 167.66M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | -29.62M | |||
Current Ratio (Q) | 1.669 | |||
Book Value Per Share (Q) | -$0.20 | |||
Total Assets (Q) | 323.06M | |||
Total Current Liabilities (Q) | 100.44M | |||
Total Debt (Q) | 271.45M | |||
Total Liabilities (Q) | 352.68M | |||
Total Common Equity (Q) | -29.62M | |||
Cash Flow | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | 4.88M | |||
Cash from Financing (TTM) | 36.17M | |||
Net Change in Cash (TTM) | 4.07M | |||
Levered Free Cash Flow (TTM) | -27.81M | |||
Cash from Operations (TTM) | -36.98M | |||